Clinical Trials

80 enrolled

Gastric Adenocarcinoma

NCT02867956 2026-03-10

Apatinib and Etoposide in Patients With Platinum Resistant or Refractory Ovarian Cancer

35 enrolled

Ovarian Neoplasms

NCT03083041 2026-03-03

A Study of SHR-1210 in Combination With Apatinib in Advanced Non-Small Cell Lung Cancer(NSCLC)

210 enrolled 11 charts

Carcinoma, Non-Small-Cell Lung

NCT07033819 2026-02-27

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

48 enrolled

Ovarian Neoplasms

NCT05451290 2026-02-12

Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer

Advanced Biliary Tract Carcinoma

NCT05139095 2026-02-05

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

70 enrolled

Gestational Trophoblastic Disease

NCT06693128 2026-01-28

Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer

80 enrolled

Tumor-Agnostic

Adenocarcinoma

NCT07357532 2026-01-22

Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD

44 enrolled

Small Cell Lung Carcinoma

NCT07314372 2026-01-20

FAD-HCC-001

86 enrolled

Carcinoma, Hepatocellular

NCT07353684 2026-01-20

Adebrelimab, Apatinib & SOX for Conversion Therapy in Advanced Gastric/GEJ Cancer

49 enrolled

Adebrelimab

NCT07324473 2026-01-07

Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study

65 enrolled

Carcinoma, Hepatocellular

NCT07311408 2025-12-31

SHR-2554

40 enrolled

Stomach Neoplasms

NCT05235100 2025-12-11

SPARE-02

Sarcoma

NCT06576973 2025-12-02

Adbelimumab Combined With Chemotherapy and Apatinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

35 enrolled

Esophageal Squamous Cell Carcinoma

NCT07157969 2025-12-01

ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC

300 enrolled

Carcinoma, Hepatocellular

NCT06925516 2025-11-28

ACADEMY

38 enrolled

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT06281886 2025-11-17

Induction Immuno-chemotherapy and Concurrent Chemoradiotherapy With or Without Apatinib in Unresectable, Locally Advanced Esophageal Squamous Cell Carcinoma

170 enrolled

Esophageal Squamous Cell Carcinoma

NCT06349317 2025-09-29

Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT

33 enrolled

Carcinoma, Hepatocellular

NCT07192848 2025-09-25

Adebrelimab + Apatinib in Advanced HCC Post-Systemic Therapy

47 enrolled

Carcinoma, Hepatocellular

NCT06145308 2025-09-15

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

39 enrolled

Head & Neck

Salivary Gland Neoplasms

NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

276 enrolled

Other neoplasm

Malignant Neoplasms of Digestive Organs

NCT07105748 2025-08-17

TASK-05

45 enrolled

Liver Neoplasms

NCT05156970 2025-07-31

Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC

81 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04560127 2025-07-10

Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer

20 enrolled

EndocrineHead & Neck

Radioactive Iodine-refractory Differentiated Thyroid Cancer

NCT03777124 2025-07-04

Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer

Phase 2 Terminated

25 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07031154 2025-06-22

A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer

43 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04625803 2025-06-17

Neoadjuvant Therapy for Locally Advanced Colon Cancer

64 enrolled 11 charts

Colonic Neoplasms

NCT06831175 2025-06-03

Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma

28 enrolled

Endocrine

Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT06429696 2025-05-28

PD-L1 Inhibitor Combined With Apatinib as First-line Maintenance Treatment for Extensive-stage Small Cell Lung Cancer

40 enrolled

Small Cell Lung Cancer Extensive Stage

NCT04072042 2025-05-14

BIOVAS

Sarcoma

NCT06483282 2025-04-15

A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer

38 enrolled

Small Cell Lung Cancer Limited Stage

NCT04195828 2025-04-01

Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer

106 enrolled

Advanced Gastric Cancer

NCT06881017 2025-03-18

Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping

140 enrolled

Stomach Neoplasms

NCT05512481 2025-03-03

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

60 enrolled

Dermatologic

Melanoma

NCT05192798 2025-02-27

Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC

128 enrolled

Breast

Triple Negative Breast Neoplasms

NCT04863430 2025-02-21

Apatinib with Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma of the Stomach

Phase 2 Withdrawn

Stomach Neoplasms

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

93 enrolled

Genitourinary

Metastatic Castration Resistant Prostate Cancer

NCT06792162 2025-01-24

PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer

20 enrolled

Stomach Neoplasms

NCT06786312 2025-01-22

A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer

34 enrolled

Small Cell Lung Carcinoma

NCT06771154 2025-01-13

A-CAPE

140 enrolled

Endometrial Neoplasms

NCT06308575 2025-01-10

A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma

Phase 2 Withdrawn

CNS

Esthesioneuroblastoma, Olfactory

NCT06764368 2025-01-08

Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors

39 enrolled

EndocrineNET

Neuroendocrine Tumors

NCT06749691 2024-12-27

LIAES

Small Cell Lung Carcinoma

NCT03878472 2024-12-16

Neoadjuvant Immunotherapy for Resectable Gastric Cancer

25 enrolled

Stomach Neoplasms

NCT06418594 2024-12-10

Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis

Breast

HER2-negative Breast Cancer Brain Metastases

NCT06482086 2024-12-05

Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid Cancer

75 enrolled

Head & Neck

Locally Advanced Thyroid Gland Carcinoma

NCT06700421 2024-11-22

Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis

32 enrolled

Radiation Pneumonitis

NCT06694324 2024-11-19

First-line Treatment of Advanced/unresectable DDLPS

49 enrolled

Sarcoma

Liposarcoma, Sarcoma

NCT06632522 2024-10-09

Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients .

46 enrolled

Liver Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer